Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Characterization of Relapse and Second-Line Therapy in Lenalidomide-Refractory, Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: A Subanalysis of the Phase 3 First Trial

Salmon Manier, Meletios A. Dimopoulos, MD, Cyrille Hulin, MD, Xavier Leleu, MD PhD, Michel Delforge, Katja C. Weisel, MD, Ruiyun Jiang, Shankar Srinivasan, PhD MBA, Bruno Costa, Suzanne Robinson, Thierry Facon, MD

Blood (2019) 134 (Supplement_1): 3122.

https://doi.org/10.1182/blood-2019-124557

Published: 2019

Journal Articles

Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability

Alessandra Pompa, Concetta Conticello, MD, Diana Giannarelli, PhD, Loredana Pettine, MD, Laura Paris, MD, Lucia Tognazzi, Magda Marcatti, MD, Elisabetta Antonioli, MD, Francesca Fioritoni, MD, Angela Bonalumi, MD, Silvia Mangiacavalli, Paola Bertazzoni, Iolanda Donatella Vincelli, MD, Daniele Derudas, MD, Agostina Siniscalchi, Sara Pezzatti, MD, Renato Zambello, Annalisa Citro, MD, Angelo Belotti, Alessandra Lombardo, MD, Federico Vozella, MD, Adelina Sementa, MD, Ugo Consoli, MD, Alfredo Molteni, MD, Niccolò Frungillo, MD, Massimo Gentile, MD, Gabriele Buda, MD PhD, Sara Aquino, Salvatore Palmieri, Velia Bongarzoni, MD, Alessandro Inzoli, MD, Valeria Ferla, MD, Francesca Gaia Rossi, MD, Valerio Leotta, MD, Alessandra Romano, MD PhD, Federica Elia, MD, Vittorio Del Fabro, MD, Guido Montanaro, MD, Francesca Cavallaro, MD, Monica Galli, Luca Baldini, MD PhD

Blood (2019) 134 (Supplement_1): 5555.

https://doi.org/10.1182/blood-2019-125098

Published: 2019

Journal Articles

Efficacy and Feasibility of Dose/Schedule-Adjusted Rd-R Vs. Continuous Rd in Elderly and Intermediate-Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients: RV-MM-PI-0752 Phase III Randomized Study

Blood (2018) 132 (Supplement 1): 305.

https://doi.org/10.1182/blood-2018-99-111796

Published: 2018

Journal Articles

A Matching-Adjusted Indirect Treatment Comparison of Daratumumab-Bortezomib-Melphalan-Prednisone Versus Lenalidomide-Dexamethasone Continuous, Lenalidomide-Dexamethasone 18 Months, and Melphalan-Prednisone-Thalidomide

Meletios A Dimopoulos, MD, Michele Cavo, MD, Maria-Victoria Mateos, MD PhD, Thierry Facon, Bart Heeg, PhD, Sophie van Beekhuizen, Sandhya Nair, Marta Pisini, MBA, Annette Lam, Mary Slavcev

Blood (2018) 132 (Supplement 1): 3551.

https://doi.org/10.1182/blood-2018-99-113517

Published: 2018

Journal Articles

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

Blood (2018) 131 (3): 301–310.

https://doi.org/10.1182/blood-2017-07-795047

Published: 2018

Includes: Supplemental data

Journal Articles

Inferior Clinical Outcomes with Fixed Duration Therapy for Transplant Ineligible Myeloma Patients: UK Real-World Data in Comparison with First Trial (MM-020)

Faye A Sharpley, MBBChir, MA, MRCP, MSc BA, Faouzi Djebbari, MSc, Jaimal Kothari, John Lynes, Su McLain-Smith, Karthik Ramasamy

Blood (2017) 130 (Supplement 1): 3404.

https://doi.org/10.1182/blood.V130.Suppl_1.3404.3404

Published: 2017

Journal Articles

Continuous Treatment with Lenalidomide Improves Outcomes in Newly Diagnosed Myeloma Patients Not Eligible for Autologous Stem Cell Transplant: Results of the Myeloma XI Trial

Blood (2017) 130 (Supplement 1): 1854.

https://doi.org/10.1182/blood.V130.Suppl_1.1854.1854

Published: 2017

Journal Articles

Final Analysis of Overall Survival from the First Trial

Blood (2016) 128 (22): 241.

https://doi.org/10.1182/blood.V128.22.241.241

Published: 2016

Journal Articles

Lenalidomide-Based Treatment for Newly Diagnosed Multiple Myeloma Patients, Ineligible for Transplant: A Healthcare Cost-Impact Analysis in Europe

Stephen A Schey, Casado Montero, Chloe Stengel-Tosetti, Craig Gibson, Sujith Dhanasiri

Blood (2015) 126 (23): 3304.

https://doi.org/10.1182/blood.V126.23.3304.3304

Published: 2015

Journal Articles

Outcome with Lenalidomide Plus Dexamethasone Followed By Early Autologous Stem Cell Transplantation in the ECOG-ACRIN E4A03 Randomized Clinical Trial: Long-Term Follow-up

Noa Biran, MD, Susanna Jacobus, David Siegel, MD PhD, Natalie Scott Callander, MD, Rafael Fonseca, MD, David H. Vesole, MD, Michael E. Williams, MD, Rafat Abonour, MD, Michael S Katz, BS,MBA, S. Vincent Rajkumar, Philip R. Greipp, MD

Blood (2015) 126 (23): 3174.

https://doi.org/10.1182/blood.V126.23.3174.3174

Published: 2015

Journal Articles

A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD-lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

Elizabeth K. O'Donnell, MD, Jacob P. Laubach, MD, Andrew J. Yee, MD, Carol A. Huff, MD, Frank G. Basile, MD, Philip M. Wade, Jr., MD, Claudia E. Paba-Prada, MD, Irene M. Ghobrial, MD, Robert L. Schlossman, MD, Nicole R. Couture, BSN, RN, Lauren Doherty, Hannah Lyons, Caroline English, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Noopur S. Raje, MD

Blood (2015) 126 (23): 4217.

https://doi.org/10.1182/blood.V126.23.4217.4217

Published: 2015

Journal Articles

A Frailty Scale Predicts Outcomes of Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone on the First Trial

Thierry Facon, Cyrille Hulin, Meletios A. Dimopoulos, Andrew Belch, Nathalie Meuleman, Mohamad Mohty, Wen-Ming Chen, Kihyun Kim, Elena Zamagni, Paula Rodriguez-Otero, MD PhD, William Renwick, Christian Rose, Adrian Tempescul, Antonio Palumbo, Shien Guo, Michael Sturniolo, Annette Ervin-Haynes, Jean-Paul Fermand

Blood (2015) 126 (23): 4239.

https://doi.org/10.1182/blood.V126.23.4239.4239

Published: 2015

Journal Articles

Continuous Treatment with Lenalidomide and Low-Dose Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma in Asia: Subanalysis of the First Trial

Blood (2015) 126 (23): 4240.

https://doi.org/10.1182/blood.V126.23.4240.4240

Published: 2015

Journal Articles

Impact of Cytogenetics on Outcomes of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone in the First (MM-020) Trial

Blood (2015) 126 (23): 730.

https://doi.org/10.1182/blood.V126.23.730.730

Published: 2015

Journal Articles

Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone (Rd): The First Trial

Blood (2014) 124 (21): 81.

https://doi.org/10.1182/blood.V124.21.81.81

Published: 2014

Journal Articles

Impact of Renal Impairment (RI) on Outcomes after Treatment (Tx) with Lenalidomide and Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): First Trial Results

Blood (2014) 124 (21): 2112.

https://doi.org/10.1182/blood.V124.21.2112.2112

Published: 2014

Journal Articles

Healthcare Resource Utilization Trends over Time with Continuous Lenalidomide Treatment (Tx) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM)

Katja Weisel, MD, Dan T. Vogl, Michel Delforge, MD PhF, Kevin Song, Meletios Dimopoulos, Jamie Cavenagh, Cyrille Hulin, Philippe Rodon, Bertrand Arnulf, Robin Foá, MD, Albert Oriol, MD, Shien Guo, Mara Silvia Monzini, Jason Van Oostendorp, Annette Ervin-Haynes, Thierry Facon, MD

Blood (2014) 124 (21): 1326.

https://doi.org/10.1182/blood.V124.21.1326.1326

Published: 2014

Journal Articles

The Outcomes of Elderly Multiple Myeloma Patients Treated in the United States

Lauren Bonomo, Jerry Lue, Ajai Chari, MD

Blood (2014) 124 (21): 5756.

https://doi.org/10.1182/blood.V124.21.5756.5756

Published: 2014

Journal Articles

Impact of Response Quality on Survival Outcomes in Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Results from the First Trial

Blood (2014) 124 (21): 3458.

https://doi.org/10.1182/blood.V124.21.3458.3458

Published: 2014

Journal Articles

Interpretation and Application of the International Myeloma Working Group (IMWG) Criteria: Proposal for Uniform Assessment and Reporting in Clinical Trials Based on the First Study Independent Response Adjudication Committee (IRAC) Experience

Joan Blade, Stefan Knop, MD, Adam D. Cohen, MD, Jatin J. Shah, Ralph M. Meyer

Blood (2014) 124 (21): 3460.

https://doi.org/10.1182/blood.V124.21.3460.3460

Published: 2014

NARROW

Characterization of Relapse and Second-Line Therapy in Lenalidomide-Refractory, Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: A Subanalysis of the Phase 3 First Trial

Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability

Efficacy and Feasibility of Dose/Schedule-Adjusted Rd-R Vs. Continuous Rd in Elderly and Intermediate-Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients: RV-MM-PI-0752 Phase III Randomized Study

A Matching-Adjusted Indirect Treatment Comparison of Daratumumab-Bortezomib-Melphalan-Prednisone Versus Lenalidomide-Dexamethasone Continuous, Lenalidomide-Dexamethasone 18 Months, and Melphalan-Prednisone-Thalidomide

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

Inferior Clinical Outcomes with Fixed Duration Therapy for Transplant Ineligible Myeloma Patients: UK Real-World Data in Comparison with First Trial (MM-020)

Continuous Treatment with Lenalidomide Improves Outcomes in Newly Diagnosed Myeloma Patients Not Eligible for Autologous Stem Cell Transplant: Results of the Myeloma XI Trial

Final Analysis of Overall Survival from the First Trial

Lenalidomide-Based Treatment for Newly Diagnosed Multiple Myeloma Patients, Ineligible for Transplant: A Healthcare Cost-Impact Analysis in Europe

Outcome with Lenalidomide Plus Dexamethasone Followed By Early Autologous Stem Cell Transplantation in the ECOG-ACRIN E4A03 Randomized Clinical Trial: Long-Term Follow-up

A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD-lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

A Frailty Scale Predicts Outcomes of Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone on the First Trial

Continuous Treatment with Lenalidomide and Low-Dose Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma in Asia: Subanalysis of the First Trial

Impact of Cytogenetics on Outcomes of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone in the First (MM-020) Trial

Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone (Rd): The First Trial

Impact of Renal Impairment (RI) on Outcomes after Treatment (Tx) with Lenalidomide and Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): First Trial Results

Healthcare Resource Utilization Trends over Time with Continuous Lenalidomide Treatment (Tx) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM)

The Outcomes of Elderly Multiple Myeloma Patients Treated in the United States

Impact of Response Quality on Survival Outcomes in Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Results from the First Trial

Interpretation and Application of the International Myeloma Working Group (IMWG) Criteria: Proposal for Uniform Assessment and Reporting in Clinical Trials Based on the First Study Independent Response Adjudication Committee (IRAC) Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only